tradingkey.logo

Precigen Inc

PGEN
查看詳細走勢圖
4.160USD
-0.030-0.72%
收盤 12/26, 16:00美東報價延遲15分鐘
1.47B總市值
虧損本益比TTM

Precigen Inc

4.160
-0.030-0.72%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.72%

5天

-3.70%

1月

+11.23%

6月

+190.91%

今年開始到現在

+271.43%

1年

+463.15%

查看詳細走勢圖

TradingKey Precigen Inc股票評分

單位: USD 更新時間: 2025-12-26

操作建議

Precigen Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在藥品行業排名83/158位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價8.50。中期看,股價處於上升通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Precigen Inc評分

相關信息

行業排名
83 / 158
全市場排名
216 / 4563
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 3 分析師
買入
評級
8.500
目標均價
+130.35%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Precigen Inc亮點

亮點風險
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
業績增長期
公司處於發展階段,最新年度總收入3.92M美元
估值合理
公司最新PE估值-2.93,處於3年歷史合理位
機構加倉
最新機構持股222.21M股,環比增加7.20%
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉,最新持倉1.15K股
活躍度增加
近期活躍度增加,過去20天平均換手率5.55

Precigen Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Precigen Inc簡介

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
公司代碼PGEN
公司Precigen Inc
CEOSabzevari (Helen)
網址https://precigen.com/

常見問題

Precigen Inc(PGEN)的當前股價是多少?

Precigen Inc(PGEN)的當前股價是 4.160。

Precigen Inc 的股票代碼是什麼?

Precigen Inc的股票代碼是PGEN。

Precigen Inc股票的52週最高點是多少?

Precigen Inc股票的52週最高點是5.225。

Precigen Inc股票的52週最低點是多少?

Precigen Inc股票的52週最低點是0.692。

Precigen Inc的市值是多少?

Precigen Inc的市值是1.47B。

Precigen Inc的淨利潤是多少?

Precigen Inc的淨利潤為-126.23M。

現在Precigen Inc(PGEN)的股票是買入、持有還是賣出?

根據分析師評級,Precigen Inc(PGEN)的總體評級為買入,目標價格為8.500。

Precigen Inc(PGEN)股票的每股收益(EPS TTM)是多少

Precigen Inc(PGEN)股票的每股收益(EPS TTM)是-1.418。
KeyAI